Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma.

Abstract Metastatic melanoma is highly fatal. Within the tumor microenvironment, the role of cancer-associated fibroblasts (CAFs) in melanoma metastasis and progression is relatively understudied. The matricellular protein CCN2 (formerly termed connective tissue growth factor, CTGF) is overexpressed, in a fashion independent of BRAF mutational status, by CAFs in melanoma. Herein, we find, in human melanoma patients, that CCN2 expression negatively correlates with survival and positively correlates with expression of neovascularization markers. To assess the role of CAFs in melanoma progression, we used C57BL/6 mice expressing a tamoxifen-dependent cre recombinase expressed under the control of a fibroblast-specific promoter/enhancer (COL1A2) to delete CCN2 postnatally in fibroblasts. Mice deleted or not for CCN2 in fibroblasts were injected subcutaneously with B16-F10 melanoma cells. Loss of CCN2 in CAFs resulted in reduced CAF activation, as detected by staining with anti-α-smooth muscle actin antibodies, and reduced tumor-induced neovascularization, as detected by micro-computed tomography (micro-CT) and staining with anti-CD31 antibodies. CCN2-deficient B16(F10) cells were defective in a tubule formation/vasculogenic mimicry assay in vitro. Mice deleted for CCN2 in CAFs also showed impaired vasculogenic mimicry of subcutaneously-injected B16-F10 cells in vivo. Our results provide new insights into the cross-talk among different cell types in the tumor microenvironment and suggest CAFs play a heretofore unappreciated role by being essential for tumor neovascularization via the production of CCN2. Our data are consistent with the hypothesis that activated CAFs are essential for melanoma metastasis and that, due to its role in this process, CCN2 is a therapeutic target for melanoma. Highlights • In human patients, CCN2 negatively correlates with disease-free outcome and positively with expression of angiogenic markers. • Loss of CCN2 in CAFs resulted in reduced CAF activation and tumor-induced neovascularization including impaired vasculogenic mimicry and reduced expression of proangiogenic proteins. • Our results provide suggest CAFs play a heretofore unappreciated role by being essential for tumor neovascularization via the production of CCN2. • Targeting CAF activation, for example by impairing the action of CCN2, represents a novel therapeutic approach for melanoma. • We provide the first genetic evidence linking CCN2 to tumor neovascularization consistent with the notion that CCN2 represents a novel therapeutic approach to treat melanoma. [ABSTRACT FROM AUTHOR]